Relation of clinical symptoms to apomorphine-stimulated growth hormone release in mood-incongruent psychotic patients.

No abstract is available for this paper.

• Publication year

  1986

• Venue

  Archives of General Psychiatry

• Publication date

  1986-12-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1001/ARCHPSYC.1986.01800120048010PMID 3778112
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Down-regulation of central dopamine receptors in schizophrenia.

  1985cited by this paper
• Plasma growth hormone responses to constant infusions of human pancreatic growth hormone releasing factor. Intermittent secretion or response attenuation.

  1984cited by this paper
• Growth hormone and prolactin response to apomorphine in schizophrenia and the major affective disorders. Relation to duration of illness and depressive symptoms.

  1984cited by this paper
• Mood-incongruent versus mood-congruent psychosis: differential antipsychotic response to lithium therapy.

  1984cited by this paper
• Impact of Lithium Therapy on Core Psychotic Symptoms of Schizophrenia

  1984cited by this paper
• Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.

  1984cited by this paper
• Effect of subchronic lithium treatment on apomorphine-induced change in prolactin and growth hormone secretion.

  1983cited by this paper
• Growth hormone levels and lithium ratios as predictors of success of lithium therapy in schizophrenia.

  1982cited by this paper
• Drug-induced growth hormone and prolactin responses in schizophrenia research.

  1982cited by this paper
• Negative v positive schizophrenia. Definition and validation.

  1982cited by this paper
• The dopamine hypothesis: an overview of studies with schizophrenic patients.

  1982cited by this paper
• Dopamine receptors, neuroleptics, and schizophrenia.

  1981cited by this paper
• Impaired growth hormone secretion in the adult population: relation to age and adiposity.

  1981cited by this paper
• Opiate and neuroleptic receptor alterations in human schizophrenic brain tissue.

  1980cited by this paper
• Molecular pathology of schizophrenia: more than one disease process?

  1980cited by this paper
• Brain locations controlling the behavioral effects of chronic amphetamine intoxication

  1980cited by this paper
• Neuroendocrine Effects of Apomorphine: Characterization of Response Patterns and Application to Schizophrenia Research

  1979cited by this paper
• Effect of clozapine on apomorphine-induced growth hormone secretion and serum prolactin concentrations in schizophrenia.

  1979cited by this paper
• A diagnostic interview: the schedule for affective disorders and schizophrenia.

  1978cited by this paper
• Binding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains

  1978cited by this paper
• Mechanism of the antipsychotic effect in the treatment of acute schizophrenia.

  1978cited by this paper
• Increased dopamine-receptor sensitivity in schizophrenia.

  1978cited by this paper
• Effect of haloperidol and apomorphine treatment on dopamine receptors in pituitary and striatum.

  1978cited by this paper
• Biochemical Actions of Neuroleptic Drugs: Focus on the Dopamine Receptor

  1978cited by this paper
• A neuroendocrine study of supersensitivity in tardive dyskinesia.

  1977cited by this paper
• Dopamine and Schizophrenia: A Reappraisal in the Light of Clinical Studies with Clozapine *

  1977cited by this paper
• Postsynaptic supersensitivity in schizophrenia.

  1977cited by this paper
• Dopamine receptor alteration in schizophrenia: Neuroendocrine evidence

  1976cited by this paper
• Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with or without oral dyskinesia, withdrawn from chronic neuroleptic therapy.

  1976cited by this paper
• Cerebrospinal fluid amine metabolites in acute schizophrenia.

  1975cited by this paper
• Apomorphine: effect on growth hormone.

  1975cited by this paper
• A Checklist for the Diagnosis of Schizophrenia

  1972cited by this paper
• The Brief Psychiatric Rating Scale

  1962cited by this paper

• Dopaminergic, Noradrenergic, Adrenal, and Thyroid Abnormalities in Psychotic and Affective Disorders

  2020cites this paper
• The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future

  2018cites this paper
• study of the growth hormone response to apomorphine. Psychotic and depressive symptoms in Parkinson's disease. A

  2012cites this paper
• Immediate Serum Growth Hormone Decrease as a Potential Index of Dopamine-Related Response to Electroconvulsive Therapy in Schizophrenic Patients

  2011cites this paper
• ASSESSMENT OF GENETIC AND ENVIRONMENTAL FACTORS IN ANIMAL MODELS OF SCHIZOPHRENIA

  2011cites this paper
• All Roads to Schizophrenia Lead to Dopamine Supersensitivity and Elevated Dopamine D2High Receptors

  2011cites this paper
• Late Prenatal Immune Activation in Mice Leads to Behavioral and Neurochemical Abnormalities Relevant to the Negative Symptoms of Schizophrenia

  2010cites this paper
• Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia

  2004cites this paper
• The Blunted Plasma Cortisol Response to Apomorphine and Its Relationship to Treatment Response in Patients with Schizophrenia

  2001influential citation
• Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses.

  2001cites this paper
• Elevated response of growth hormone to graded doses of apomorphine in schizophrenic patients.

  1998cites this paper
• Psychoneuroendocrinology of schizophrenia.

  1998cites this paper
• Negative Symptoms of Schizophrenia: Methodological Issues, Biochemical Findings and Efficacy of Neuroleptic Treatment

  1996cites this paper
• The psychobiology of the acute schizophrenic episode

  1996cites this paper
• Multihormonal responses to apomorphine in mental illness.

  1995cites this paper
• Psychotic and Depressive Symptoms in Parkinson's Disease a Study of the Growth Hormone Response to Apomorphine

  1995cites this paper
• Psychotic Continuum or Distinct Entities: Perspective from Psychopharmacology

  1995cites this paper
• Biochemical findings of negative symptoms in schizophrenia and their putative relevance to pharmacologic treatment. A review.

  1994cites this paper
• Biochemische Hypothesen zur Negativ-Symptomatik der Schizophrenie

  1994cites this paper
• Factor analysis of schizophrenic symptoms and comparison of different rating scales.

  1993cites this paper
• Neurochemistry and neuroendocrinology of schizophrenia: a selective review.

  1993cites this paper
• The Concept of Supersensitivity Psychosis

  1992cites this paper
• Behavioral and biochemical effects of methylphenidate in schizophrenic and nonschizophrenic patients.

  1991cites this paper
• Basal and haloperidol-stimulated prolactin in neuroleptic-free men with schizophrenia defined by 11 diagnostic systems.

  1990cites this paper
• Relationship of psychotic symptoms to haloperidol‐stimulated prolactin release

  1990cites this paper
• Length of psychiatric hospitalization and prediction of antipsychotic response.

  1990cites this paper
• Neuroendocrinology of Schizoaffective Disorders

  1989cites this paper
• Apomorphine in the evaluation of dopaminergic function in man.

  1988cites this paper
• Growth hormone response to edrophonium in Alzheimer's disease.

  1987cites this paper
• Growth hormone response to apomorphine and diagnosis: a comparison of three diagnostic systems.

  1986cites this paper
• Down-regulation of central dopamine receptors in schizophrenia.

  1985cites this paper